MNPR
Monopar Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$117.56
−0.84%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 14.8M | 9.9B | 13.0M | 5.6M | 7.6M |
| SG&A Expense | 1.7B | 6.8B | 3.2M | 3.2M | 2.9M |
| General & Admin Expense | 1.7B | 6.8B | 3.2M | 3.2M | 2.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (1.7B) | (16.7B) | — | — | — |
| Total Operating Expenses | 22.1M | 16.7M | 16.2M | 8.8M | 10.5M |
| Cost and Expenses | 22.1M | 16.7M | 16.2M | 8.8M | 10.5M |
| Operating Income (EBIT) | (22.1M) | (16.7M) | (16.2M) | (8.8M) | (10.5M) |
| Non-Operating | |||||
| Interest Income | 4.2M | 3.0M | 404.0K | 429.0K | 21.2K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 4.2M | 3.0M | 404.0K | 429.0K | 21.2K |
| Other Non-Op Income/Expense | 4.3M | 3.0M | 575.3K | 429.0K | 21.2K |
| Non-Operating Income (excl Interest) | (3.6M) | (3.0M) | (575.3K) | (429.0K) | (21.2K) |
| EBT (Pre-Tax Income) | (17.8M) | (13.7M) | (15.6M) | (8.4M) | (10.5M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (17.8M) | (13.7M) | (15.6M) | (8.4M) | (10.5M) |
| Earnings from Cont. Ops | (17.8M) | (13.7M) | (15.6M) | (8.4M) | (10.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (17.8M) | (13.7M) | (15.6M) | (8.4M) | (10.5M) |
| Per Share | |||||
| Basic EPS | ($2.34) | ($1.85) | ($1.36) | ($0.58) | ($0.83) |
| Diluted EPS | ($2.34) | ($1.85) | ($1.36) | ($0.58) | ($0.83) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 8.5M | 7.4M | 11.4M | 14.5M | 12.7M |
| Diluted Shares Outstanding | 8.5M | 7.4M | 11.5M | 14.5M | 12.7M |
| Profitability Metrics | |||||
| EBITDA | (18.5M) | (13.7M) | (15.6M) | (8.4M) | (10.5M) |
| D&A | — | — | — | — | — |
| EBIT | (18.5M) | (13.7M) | (15.6M) | (8.4M) | (10.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026